著者
Junichiro Irie Emi Inagaki Masataka Fujita Hideaki Nakaya Masanori Mitsuishi Shintaro Yamaguchi Kazuya Yamashita Shuhei Shigaki Takashi Ono Hideo Yukioka Hideyuki Okano Yo-ichi Nabeshima Shin-ichiro Imai Masato Yasui Kazuo Tsubota Hiroshi Itoh
出版者
The Japan Endocrine Society
雑誌
Endocrine Journal (ISSN:09188959)
巻号頁・発行日
pp.EJ19-0313, (Released:2019-11-02)
被引用文献数
8 8

Recent studies have revealed that decline in cellular nicotinamide adenine dinucleotide (NAD+) levels causes aging-related disorders and therapeutic approaches increasing cellular NAD+ prevent these disorders in animal models. The administration of nicotinamide mononucleotide (NMN) has been shown to mitigate aging-related dysfunctions. However, the safety of NMN in humans have remained unclear. We, therefore, conducted a clinical trial to investigate the safety of single NMN administration in 10 healthy men. A single-arm non-randomized intervention was conducted by single oral administration of 100, 250, and 500 mg NMN. Clinical findings and parameters, and the pharmacokinetics of NMN metabolites were investigated for 5 h after each intervention. Ophthalmic examination and sleep quality assessment were also conducted before and after the intervention. The single oral administrations of NMN did not cause any significant clinical symptoms or changes in heart rate, blood pressure, oxygen saturation, and body temperature. Laboratory analysis results did not show significant changes, except for increases in serum bilirubin levels and decreases in serum creatinine, chloride, and blood glucose levels within the normal ranges, independent of the dose of NMN. Results of ophthalmic examination and sleep quality score showed no differences before and after the intervention. Plasma concentrations of N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide were significantly increased dose-dependently by NMN administration. The single oral administration of NMN was safe and effectively metabolized in healthy men without causing any significant deleterious effects. Thus, the oral administration of NMN was found to be feasible, implicating a potential therapeutic strategy to mitigate aging-related disorders in humans.

言及状況

外部データベース (DOI)

Twitter (14 users, 15 posts, 27 favorites)

<参考文献> https://t.co/luJiFgfTHz https://t.co/uM6XTre4VS https://t.co/YaQG4uZclb https://t.co/3Ta3dqCRMJ https://t.co/anvixv5rhh https://t.co/64LcS96nEG https://t.co/DsxomOMrFN https://t.co/pB1YmFCYgB https://t.co/oYr3RswVW8 https://t.co/hkvwJ3TyZC
陰謀論界隈が物語の創作に励んでいる最中にも、科学者は着実に人類の歩みを前に進めている。 若返りの効果なし。心臓への副作用が確認されているアドレノクロム。 他方、若返りあり、慶応により安全性にもお墨付きを得たNMN。 https://t.co/zbRWEsb64A アドレノクロムの立場なし
@TradeandMoney https://t.co/QgAnTtBoPR https://t.co/sYE3PWkf2K https://t.co/yR5w5JTeQy https://t.co/kD2eELhcwB https://t.co/1xmz326aeD https://t.co/MneDLvXMJX https://t.co/ibaX8Z6cdn
@FriendAsking4a @davidasinclair @onemoex @booksmithtweets @mdlaplante Dr. Charles Brenner's life's work is a sham. NR is completely ineffective and this has been proven in many scientific studies. NMN and NAD+ are the most effective at raising systemic NAD+ levels. Get wise. https://t.co/0ITBZLQ0A4
@MattYousefzadeh @CharlesMBrenner Matt, ironically, you're being hoodwinked by Dr. Brenner. He's being paid to bring down NMN, which is a safe compound and highly effective. NR is 100% ineffective. Get wise. https://t.co/0ITBZLQ0A4
https://t.co/18TuxXNtcB this is one nmn study on safty @davidasinclair
NMN human study (finally): "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men" https://t.co/2tAwJYCGMA https://t.co/aHzvTM8Rg2

収集済み URL リスト